Related Experiment Video

Updated: Nov 23, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K

Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure

Bao-Hua Li1, Kuai-Fa Fang1, Pei-Huan Lin1

  • 1Department of Cardiology, Affiliated Huiyang Hospital of Southern Medical University, Huizhou, China.

Clinical Hemorheology and Microcirculation
|January 2, 2021
PubMed

Insights

Sacubitril valsartan improved cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction (HFrEF). This study found significant improvements in left ventricular ejection fraction and flow-mediated vasodilation compared to perindopril.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure with reduced ejection fraction (HFrEF) significantly impacts cardiac and vascular health.
  • Current treatments aim to improve cardiac function and endothelial function, but further advancements are needed.

Purpose of the Study:

  • To evaluate the effects of sacubitril valsartan on cardiac function and vascular endothelial function in HFrEF patients.
  • To compare sacubitril valsartan with perindopril in managing HFrEF.

Main Methods:

  • 80 HFrEF patients were randomized into two groups: observation (sacubitril valsartan) and control (perindopril).
  • Both groups received conventional treatment for 12 weeks.
  • Key parameters assessed included left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), flow-mediated vasodilatory function (FMD), plasma Ang II, endothelin 1 (ET-1), calcitonin gene-related peptide (CGRP), nitric oxide (NO), and NO synthase (NOS).

Main Results:

  • Sacubitril valsartan significantly improved LVEF, FMD, CGRP, NO, and NOS compared to baseline and the perindopril group.
  • LVEDD, Ang II, and ET-1 levels were significantly reduced in the sacubitril valsartan group compared to the perindopril group.
  • These improvements indicate enhanced cardiac and endothelial function with sacubitril valsartan.

Conclusions:

  • Sacubitril valsartan demonstrates potential in improving both cardiac and endothelial function in HFrEF patients.
  • The findings suggest sacubitril valsartan may be a beneficial therapeutic option for HFrEF management.
Abstract

Keywords:
Sacubitril valsartancardiac functionchronic heart failureendothelial functionleft ventricular ejection fraction

More Related Videos

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

19.7K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
673
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
93
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
248
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
616
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
563
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.2K